Log In
BCIQ
Print this Print this
 

PGN-201

  Manage Alerts
Collapse Summary General Information
Company bluebird bio Inc.
DescriptionHoming endonuclease
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$155.7M

0

$135.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/30/2014

$155.7M

0

$135.0M

Get a free BioCentury trial today